Development of a preliminary framework for informing the risk analysis and risk management of nanoparticles

Kara Morgan1

  • 1Office of Planning/Office of the Commissioner/HFP-20, Rockville, MD 20857, USA. Kara.Morgan@FDA.gov

Related Concept Videos